Hyperadrenergic POTS (HyperPOTS) is a phenotype of postural orthostatic tachycardia syndrome in which standing comes with excessive activation of the sympathetic nervous system, the body’s fight-or-flight network. It is often marked by raised upright norepinephrine, a chemical messenger released by sympathetic nerves, or by a blood-pressure rise on standing.
A person still has to meet the criteria for POTS first. No single test for HyperPOTS is universally accepted, and its features can overlap with low blood volume or nerve-related mechanisms, so it is not simply too much adrenaline.
What counts as POTS to begin with?
Before any subtype, there has to be POTS. The current international expert consensus describes chronic orthostatic intolerance, meaning symptoms that appear on standing, with a sustained heart-rate increase of at least 30 beats per minute in adults, or 40 in adolescents, during 10 minutes of standing or tilt testing.
Two further conditions apply. Classical orthostatic hypotension (a significant blood-pressure drop on standing) must not be enough to explain the picture, and no other cause of tachycardia should explain it better.
A blood pressure that rises when you stand does not, on its own, mean you have HyperPOTS.
What makes POTS hyperadrenergic?
The label points to the nervous system’s response, not just the heart rate. Upright plasma norepinephrine above about 600 pg/mL has long been used as a marker. A 2026 autonomic-testing study defined hyperadrenergic features as upright norepinephrine above 600 pg/mL and/or more than three times the person’s supine level. Some patients also have an orthostatic blood-pressure rise or marked blood-pressure variability.
These thresholds are phenotyping tools, not universally accepted standalone diagnostic criteria. Symptoms often include tremulousness, palpitations, sweating, cold hands and feet, and adrenaline-like physical sensations, but a rise in norepinephrine is not proof of a single mechanism.
Elevated norepinephrine can reflect several different things: primary or central sympathetic overactivity, a compensatory response to low blood volume, a compensatory response to venous pooling linked to nerve changes, impaired norepinephrine clearance, or the effect of medications. For that reason, not every elevated-norepinephrine case is “central” HyperPOTS.
Do POTS subtypes overlap?
Yes. A September 2026 study in Clinical Autonomic Research supports that hyperadrenergic and neuropathic features commonly coexist in the same person.
Subtype labels describe mechanisms, but they don’t create clean boxes where only one can be present. Treatment may need to address more than one mechanism at once.
| Feature | Hyperadrenergic features | Neuropathic features | Hypovolemic features | Important overlap note |
|---|---|---|---|---|
| Core idea | Excessive sympathetic or noradrenergic activation on standing | Venous pooling linked to neuropathic changes | Reduced blood volume | Labels describe mechanisms, and several can coexist |
| What a high standing norepinephrine can reflect | Primary or central sympathetic overactivity | A compensatory response to venous pooling | A compensatory response to low volume | Impaired norepinephrine clearance and medications can also raise it |
| Treatment angle | Specialists may consider medicines that reduce sympathetic activity or heart rate | Addressed as part of a combined approach | May benefit from volume expansion | Treatment may need to address more than one mechanism |
What symptoms does hyperadrenergic POTS cause?
Symptoms can include:
- a fast heart rate on standing and palpitations
- tremulousness and sweating
- cold hands and feet
- lightheadedness and fatigue
- headache or migraine
- chest discomfort
- internal “adrenaline surge” sensations
- blood-pressure elevation or marked variability in some people
- anxiety-like physical sensations
- disrupted sleep in some people
Symptoms alone don’t diagnose the phenotype, because most of these occur in many other conditions.
Is hyperadrenergic POTS just anxiety?
No. POTS is a dysautonomia, a disorder of the autonomic nervous system, and anxiety does not cause it.
The sympathetic physiology can feel very similar to panic. A person can also have an anxiety disorder independently of POTS. Neither situation justifies dismissing the other.
How is hyperadrenergic POTS diagnosed?
Diagnosis starts with confirming POTS. That means measuring heart rate and blood pressure lying and standing, usually with a stand test or a tilt-table test, along with a review of your medications.
When the subtype matters for treatment, a clinician may measure plasma catecholamines, the family of chemicals that includes norepinephrine and adrenaline, lying down and upright. Autonomic reflex testing can add detail, and a September 2026 testing consensus endorsed by the American Autonomic Society and AANEM supports standardized autonomic reflex testing performed by qualified personnel.
How norepinephrine testing works
The result depends on how the sample is collected. Posture and the time allowed to equilibrate matter, supine and upright samples are interpreted together, and medications can change catecholamine results.
One lab value doesn’t reveal the whole mechanism. This is a clinician-directed test, and a home protocol can’t substitute for it.
What is the Valsalva biomarker?
The Valsalva maneuver involves forcefully breathing out against a fixed resistance, which temporarily changes blood pressure and heart rate in a measurable way. In specialist settings, it is part of autonomic testing.
A 2024 study in Hypertension reported a candidate HyperPOTS biomarker: a diastolic blood-pressure rise of more than 17 mmHg during late phase 2 of Valsalva. It was studied in a small phenotyping cohort and showed useful specificity for high sympathetic activity.
This is an emerging precision-phenotyping tool, not a standard diagnostic criterion. It shouldn’t be attempted at home to diagnose yourself.
What else can look like hyperadrenergic POTS?
Several conditions can produce a fast heart rate and adrenaline-like symptoms, and part of the work-up is to consider them where the history points that way:
- pheochromocytoma, a rare tumor that releases adrenaline-type hormones
- hyperthyroidism
- anemia
- acute dehydration
- medication or stimulant effects
- inappropriate sinus tachycardia
- supraventricular tachycardia or other tachyarrhythmias
- panic disorder, as a separate diagnosis
- orthostatic hypertension
- other dysautonomias
None of this implies that pheochromocytoma is common. It is a reason for a clinician, not a self-checklist, to guide testing.
How is hyperadrenergic POTS treated?
Treatment is individualized because the hyperadrenergic pattern can coexist with low blood volume, neuropathic features or other mechanisms. Management usually combines general POTS measures with carefully selected medications when symptoms remain limiting.
Core measures and the salt question
General POTS strategies, as described in clinical reviews, can include fluids, individualized sodium, compression, progressive physical reconditioning and trigger management.
Sodium needs care in HyperPOTS. Some people are also hypovolemic and may benefit from volume expansion, but a raised blood pressure doesn’t automatically mean you have enough blood volume. More sodium isn’t automatically appropriate when blood pressure is high, so sodium and fluid targets should be individualized with your clinician.
Medicines specialists consider
Evidence for medicines in HyperPOTS varies, and none of these should be started or adjusted without a clinician.
Low-dose propranolol has evidence in POTS generally and may help selected hyperadrenergic patients by reducing tachycardia and palpitations. Ivabradine has randomized HyperPOTS-specific evidence: a double-blind, placebo-controlled crossover trial in 22 patients found improved heart-rate control and selected quality-of-life measures. It was still a small trial.
Guanfacine rests on weaker evidence. In the 2024 biomarker study, biomarker-positive patients treated clinically with guanfacine reported more benefit, but that was a separate, uncontrolled treatment cohort, not a placebo-controlled efficacy trial. It supports further trials and specialist, phenotype-targeted use.
A 2025 observational study of clonidine showed reductions in sympathetic and heart-rate measures in HyperPOTS. Long-term follow-up was limited, and bradycardia or sinus arrhythmia occurred in some participants, so it stays specialist-directed.
A 2026 case series of only five patients reported that methyldopa improved hyperadrenergic symptoms and sleep. A five-patient series is not proof of effectiveness.
Medication review
Drugs that increase norepinephrine signaling or block norepinephrine reuptake can worsen symptoms in some people with POTS. Don’t stop stimulants, ADHD medicines, antidepressants or any other prescription on your own. The right step is a medication review with the prescribing clinician.
Does hyperadrenergic POTS go away?
There’s no guaranteed cure. Symptoms can improve with management, but long-term natural-history data in adults are limited, so remission can’t be promised.
There is no established evidence that HyperPOTS itself shortens life expectancy.
How does it relate to mast cell activation?
This is a brief answer, because the full relationship deserves its own treatment. A small 2005 Vanderbilt study described POTS patients with flushing and objective mast-cell mediator abnormalities who had a hyperadrenergic orthostatic response.
More recent evidence is much less definitive than online discussions often suggest. A 2025 systematic review found no studies that met its prespecified strict diagnostic criteria and confirmed an association between POTS and mast-cell activation disorders. The relationship therefore remains uncertain and needs better studies using validated definitions.
HyperPOTS does not diagnose MCAS, and MCAS doesn’t explain every HyperPOTS case. Flushing, tachycardia, gut symptoms or “histamine symptoms” on their own don’t meet MCAS diagnostic criteria. If mast-cell activation is genuinely suspected, see how MCAS testing is interpreted. For how histamine intolerance differs, see histamine intolerance explained.
Pregnancy, COVID, seizure-like episodes and hormones
These situations do not define HyperPOTS, but they come up often because they can change symptom patterns, diagnostic interpretation or treatment decisions. Each needs its own clinical context rather than being treated as part of one single HyperPOTS mechanism.
Pregnancy
POTS management in pregnancy needs obstetric, cardiology and autonomic review, because medication safety and volume needs differ. Specific medication advice belongs with that team.
COVID
Post-viral and Long-COVID-associated POTS are recognized. That doesn’t mean COVID causes the hyperadrenergic subtype in every case.
Seizure-like episodes
HyperPOTS does not cause epilepsy. Fainting can sometimes include brief convulsive movements, but seizure-like events need a proper clinical evaluation.
Hormones
Menstrual and endocrine factors can influence symptoms in some people, but vague hormone-balancing claims don’t describe a defined HyperPOTS mechanism.
When should you see a POTS or autonomic specialist?
Specialist assessment is particularly useful when the diagnosis is uncertain, symptoms remain disabling despite basic measures, blood pressure rises markedly or unpredictably, or treatment decisions depend on catecholamine or autonomic-reflex testing. It is also useful when several mechanisms may be overlapping and a simple subtype label is not explaining the whole picture.
New severe chest pain, significant breathing difficulty, sustained abnormal heart rhythms, or loss of consciousness need prompt medical assessment rather than being assumed to be a routine HyperPOTS episode.
Bottom line
Hyperadrenergic POTS is best understood as a POTS phenotype with excessive sympathetic activation, not as a separate disease defined by one perfect test. Upright norepinephrine, blood-pressure responses and specialist autonomic testing can help characterize the phenotype, but the findings need context because hyperadrenergic, neuropathic and hypovolemic mechanisms can overlap.
Treatment follows that same principle. General POTS measures remain important, while medications such as propranolol, ivabradine or central sympatholytics may be considered selectively according to the patient’s physiology, blood pressure, comorbidities and evidence strength.
References
- Sivakoti K, et al. International Multidisciplinary Expert Consensus. Am J Med. 2026.
- Cortez MM, et al. Autonomic testing consensus. Clin Auton Res. 2026.
- Trout J, et al. Hyperadrenergic and neuropathic features in POTS. Clin Auton Res. 2026.
- Okamoto LE, et al. Clinical Biomarkers and Response to Guanfacine. Hypertension. 2024;81(11):2237-2247.
- Raj SR, et al. Diagnosis and management of POTS. CMAJ. 2022;194:E378-E385.
- Taub PR, et al. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77(7):861-871. doi:10.1016/j.jacc.2020.12.029.
- Shibao C, et al. Hyperadrenergic POTS in mast cell activation disorders. Hypertension. 2005;45(3):385-390.
- Handy A, et al. Methyldopa for HyperPOTS: five-patient case series. Auton Neurosci. 2026.
- Lin S, et al. Using Clonidine for neuromodulation in patients with postural orthostatic tachycardia syndrome. Heart Rhythm. 2025;22(9):e781-e790. doi:10.1016/j.hrthm.2025.05.003.
- Farley M, et al. Prevalence of mast cell activation disorders and hereditary alpha tryptasemia among patients with postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome: A systematic review. Ann Allergy Asthma Immunol. 2025;135(1):97-102. doi:10.1016/j.anai.2025.03.022.
